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Purpose: Although the Peripheral Arterial Disease Rehabilitation Program (PADRx) improves walking ability and quality
of life over brief periods of follow-up, the long-term durability of results has not been established. This study examined
functional status, walking ability, and quality of life in patients several months after completion of a 12-week PADRx.
Methods: Patients who completed a PADRx were eligible for participation. A Medical Outcomes Study 36-Item Short
Form (SF-36), Walking Impairment Questionnaire (WIQ), and physical activity questionnaire were administered by
telephone. A progressive treadmill test was performed on-site.
Results: Of 63 eligible patients, 14 were lost to follow-up, 11 refused participation, and four died. Thirty-four patients
had completed PADRx 20 to 80 months previously (mean, 48.2  13.7 months), and completed the phone survey.
Fifteen patients reported exercising a minimum of 60 min/wk for 3 months (EX group), and 19 had not exercised in the
preceding 3 months (SED group). Self-reported SF-36 values were significantly different between the EX and SED
groups for Physical Function (43.3 8.2 vs 34.2 7.8), Role–Physical Function (41.2 7.7 vs 32.8 9.2), and Bodily
Pain (46.9  8.8 vs 38.9  7.1), as well as the Physical Composite (43.5  6.5 vs 34.0 vs 5.8) domains of the SF-36.
Similarly the WIQ demonstrated significant differences in Walking Distance (46.8  36.2 vs 7.8  9.4), Walking Speed
(47.5 32.6 vs 14.5 13.9), and Stair Climbing (60.6 36.6 vs 37.1 27.6), favoring the EX group. Sixteen patients,
equally distributed between the EX and SED groups, completed the progressive treadmill test. Both groups had
experienced improvement (P < .05) in claudication pain time and maximal walking time after completing the 12-week
supervised program. The EX group maintained increased claudication pain time of 121% and maximum walking time of
109% over baseline, whereas the SED group values had returned to baseline (P < .05).
Conclusions: Patients with claudication realize symptomatic and functional improvement with supervised exercise
programs. Those who continue to exercise will potentially maintain these benefits and experience improved health-related
quality of life. (J Vasc Surg 2004;39:1186-92.)Peripheral arterial disease (PAD) affects approximately
8 million to 12 million persons in the United States,
causing significant morbidity and mortality.1 There is
considerable evidence that exercise rehabilitation can im-
prove exercise performance and community-based func-
tional status of patients with claudication.2,3 Results from
previous studies demonstrate that 12 weeks of supervised
exercise training for patients with PAD improves peak
exercise performance and decreases severity of claudication
pain.4-8
Most studies have examined relatively short-term re-
sults of exercise therapy. We evaluated long-term effects on
functional status and quality of life in patients who com-
pleted a 12-week supervised vascular exercise program.
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Patients
Beginning in 1995, a vascular rehabilitation exercise
program was established, initially hospital-based and sub-
sequently offered in an independent practice setting. All
patients who completed the vascular rehabilitation exercise
program at least 12 months before this study were eligible
for participation. Regardless of site, the structure of the
12-week program was consistent throughout the study
period. Patients entered the program on a rolling admission
policy, resulting in a variable length of follow-up in the
study population.The Peripheral Arterial Disease Rehabili-
tation Program (PADRx) is open to all patients with PAD
as documented by presence of intermittent claudication,
with a resting ankle-brachial index (ABI) less than 0.9 and
a decrease in ankle pressure of 15 mm Hg or more after a
progressive treadmill protocol is administered. Therapy was
consistent throughout the study period, and consisted of
12 weeks of formal supervised exercise training with three
1-hour exercise sessions per week of treadmill training, arm
and leg ergometry, light free weight training, and flexibility
exercises. In addition, patients received counseling about
nutrition, exercise, risk factors for atherosclerosis, and po-
tential complications of cardiovascular disease. Each patient
performed a progressive treadmill test before entry in and
after completion of the exercise program.5
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The study was approved by the University of Rhode
Island institutional review board. All eligible patients were
sent a letter outlining the study and informing them that
they would be contacted by telephone. Those who agreed
to participate gave informed consent, and were adminis-
tered a 1-hour telephone survey to update their medical
history and assess quality of life, functional status, and current
exercise habits. On completion of the telephone survey
each patient was asked to return to the exercise program to
perform a follow-up progressive treadmill test. Long-term
follow-up treadmill test results were compared with base-
line and immediately post-PADRx treadmill test results.
Measures
Quality-of-life questionnaire. Health-related quality
of life was assessed with the Medical Outcomes Study
Short-Form 36, version 2 (SF-36). The SF-36 contains 36
questions that refer to patient health over the previous 4
weeks and measures eight health domains, including phys-
ical functioning, role limitations due to physical problems,
bodily pain, general health perception, vitality, social func-
tioning, role limitations due to emotional problems, and
mental health.9
Functional status questionnaire. The Walking Im-
pairment Questionnaire (WIQ) is a validated question-
naire10 designed to assess the degree of impairment expe-
rienced by patients with intermittent claudication during
daily activities.11 Regensteiner et al10 found that the WIQ
distance score is correlated (r  0.68) with peak treadmill
walking time. Although usually administered in a clinical
setting, the WIQ has good reliability and validity with
telephone administration.12 The WIQ yields scores for
walking distance, walking speed, stair-climbing ability, and
pain. Outcome is expressed as a percentage of full function.
Self-reported exercise. A questionnaire was devel-
oped to evaluate exercise habits since leaving the PADRx
(see Appendix). Patients reported the frequency, intensity,
duration, and mode of exercise since program completion,
as well as the length of time they had been involved in their
routine. Using American College of Sports Medicine
(ACSM) guidelines,13 we dichotomized individuals into
two groups on the basis of exercise duration of at least 60
min/wk during the last 3 months (exercise group, EX) or
less than 60 min/wk for the past 3 months (sedentary
group, SED). Subjective ratings of improved functional
status in a community setting were evaluated.
Treadmill testing. Before the treadmill test all pa-
tients provided written informed consent. All hemody-
namic measures were performed with the patient supine.
ABI was obtained with a standard protocol.
Exclusion criteria for treadmill testing included resting
systolic blood pressure greater than 190 mm Hg, resting
diastolic blood pressure greater than 100 mm Hg, recent
chest discomfort, frequent use of nitroglycerin for daily
activities, obvious shortness of breath, tachycardia, previ-
ously undiagnosed irregular heart rhythm, or patient refusal.Patients underwent the same validated graded treadmill
protocol performed before participation in the supervised
exercise program. In brief, the protocol begins at 1 mph
and 5% grade, and speed or grade, or both, are increased
every 5 minutes.14 At the end of each stage, blood pressure,
heart rate, and a five-point claudication scale are recorded.
Patients continue walking until they reach maximum clau-
dication pain or another clinical indication for stopping the
test.15
Statistical analysis
To examine changes in maximum walking time and
claudication pain time across time (pre-PADRx, comple-
tion of PADRx, follow-up) a multivariate repeated mea-
sures design (MANCOVA) was used. An alpha level of 0.05
was used for all tests of statistical significance. Data are
presented as mean  SD. Because there was a great deal of
variability in the amount of time elapsed since completion
of the 12-week supervised program, the number of months
since program completion was included as a covariate.
Pearson product moment correlations were used to deter-
mine any additional potential covariates or between-subject
factors to include in the repeated measures analyses. Age
and resting right and left ABI at baseline and exercise status
at follow-up were correlated with maximum walking time
and claudication pain time at follow-up. The dichotomous
variable, exercise status, was the only significant predictor
of maximum walking time (r  0.66; P  .05) and claudi-
cation pain time (r  0.66; P  .05). Therefore exercise
status was included as a between-subjects factor in the
repeated-measures MANCOVA. In the event of a signifi-
cant f value, post hoc analysis with the Bonferroni correc-
tion was used to identify which time points differed.
Since exercise status was the only significant variable in
the MANCOVA, independent sample t tests were used to
examine differences in descriptive characteristics, WIQ
scores, and health-related quality of life (SF-36) among
those individuals who continued to exercise at follow-up
versus those who were sedentary.
RESULTS
Demographic data. Sixty-three graduates of the vas-
cular exercise program were eligible for the study. Of these
patients, 18 could not be contacted (14 were lost to follow-
up, four had died) and 11 refused participation. A series of
independent-sample t tests found no significant differences
(P  .05) at baseline for individuals who agreed to partic-
ipate in the study compared with those who did not partic-
ipate, with regard to age, gender, months since program
completion, baseline ABI, claudication pain time, maxi-
mum walking time, smoking history, or presence of diabe-
tes mellitus. The study population included 34 patients, 19
men and 15 women. Average age was 74.1  9.1, mean
baseline resting ABI was 0.53  0.18, mean baseline clau-
dication pain time was 4:49 3:13 minutes, and maximum
walking time was 7:30  4:19 minutes. This follow-up
investigation was completed 20 to 80 months (mean, 48.2
 13.7 months) after completion of the PADRx.
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of the minimum guidelines of the ACSM13 as 60 or more
minutes of exercise per week for the preceding 3 months or
less than 60 minutes per week for 3 months. These groups
were clearly delineated, with the EX group exercising on
average 162.3  86.1 minutes per week and the SED
group exercising on average 0.79  2.5 minutes per week.
There was no difference between the EX and SED groups
in age, baseline resting ABI, claudication pain time, maxi-
mum walking time, or amount of time elapsed since com-
pleting the PADRx (Table I). The EX group seem less likely
to smoke (27% vs 42%) or to have diabetes (7% vs 32%) at
enrollment in the PADRx; however, these differences were
not significant.
Of those patients who were no longer exercising at
follow-up, 11 patients reported regular exercise habits for
greater than 1 year (mean, 2.5 years), four patients reported
less than 12 months of continued exercise, and four pa-
tients stopped exercising immediately after program com-
pletion. This represents a mean sedentary period from end
of regular exercise to follow-up of 24 months. Reasons
given for discontinuing regular exercise were lack of moti-
vation (n  5), orthopedic problems (n  7), general
health concerns (n  2), and unspecified (n  5).
Home-based versus clinic-based exercise. Func-
tional ability and quality of life were compared in patients
who continued to exercise on their own (n  6) and those
who continued to exercise in the maintenance phase of a
supervised program (n 9) either at the institution exercise
Table II. SF-36 scores for exercise and sedentary groups
Exercise group Sedentary group
Physical functioning 43.3  8.2 34.2  7.8*
Role–physical 41.2  7.7 32.8  9.2*
Bodily pain 46.9  8.8 38.9  7.1*
General health 47.0  9.4 41.5  9.3
Vitality 52.3  8.5 46.4  13.4
Social functioning 49.6  8.4 44.8  13.6
Role–emotional 43.7  13.1 37.7  16.8
Mental health 50.0  10.0 49.7  9.0
Physical composite score 43.5  6.5 34.0  5.8*
Mental composite score 50.7  10.3 49.3  14.1
*Difference between exercise and sedentary groups, P  .05.
Table I. Study population demographic data
Total
populatio
(n  34
Average age (y) 74.1  9.
Male gender (%) 55.9
Months since program completion 48.2  13
Resting ankle-brachial index* 0.53  0.
Claudication pain time (min)* 4.49  3.
Maximum walking time (min)* 7.30  4.
Unless otherwise specified, values represent mean  SD.
*Before peripheral arterial disease rehabilitation.clinic or at a community organized program. There were no
statistical differences between theses groups in WIQ or
SF-36 scores.
Interval interventions. Seven patients in the study,
two in the EX group and five in the SED group, underwent
vascular interventions during follow-up. Both patients in
the EX group had progression of claudication symptoms to
ischemic rest pain, requiring aortobifemoral bypass in one
patient and extensive aortobifemoral and left femoral pop-
liteal bypass grafting in the other patient. In the SED group
five patients progressed to rest pain, one with tissue loss.
Three patients were managed surgically, one with femoro-
femoral bypass, one with bilateral iliac and common femo-
ral patch endarterectomy, and one with femoro–posterior
tibial bypass. Two patients were managed with endovascu-
lar iliac stents. There were no amputations during fol-
low-up in either group.
Questionnaire scores for EX and SED groups. Re-
sults from the SF-36 are presented in Table II. The EX
group exhibited significantly higher Physical Function, Ro-
le–Physical Function, Bodily Pain, and Physical Composite
scores, compared with the SED group (P  .05). No
significant difference was found between the two groups in
five of the eight standard subscales (General Health, Vital-
ity, Social Function, Role–Emotional, and Mental Health)
or in the Mental Composite scores.
WIQ scores are presented in Fig 1. In the EX group,
distance, speed, and stair-climbing scores were significantly
higher than in the SED group (P  .05). There was no
significant difference in degree of pain between groups.
Treadmill testing. Of the 34 patients who answered
the questionnaire, 17 (nine men, eight women) partici-
pated in a follow-up progressive treadmill test; however,
one patient was unsuccessful in completing the treadmill
test, because of arthritis. Reasons for nonparticipation in
the EX group were medical (n 5) and patient refusal (n
2), and in the SED group were medical (n  5), patient
refusal (n  3), and availability (n  2). Overall, 16
patients, eight in the EX group and eight in the SED group,
completed the treadmill test.
Two patients in the EX group completed the 25-
minute protocol. Four patient tests were terminated be-
cause of shortness of breath or rise in systolic blood pressure
to 200 mm Hg or greater, and two patient tests were
Exercise
(n  15)
Sedentary
(n  19)
75.6  9.2 73.0  9.2
60 52.6
48.2  15.6 48.2  12.4
0.54  0.13 0.53  0.22
4.56  3.11 4.44  3.19
7.41  4.31 7.21  4.17n
)
1
.7
18
13
19
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SED group, two patient tests were terminated because of
rise in systolic blood pressure to 200 mm Hg or greater,
and six tests were terminated because of maximum claudi-
cation pain.
In review of treadmill testing before and after PADRx,
claudication pain time and maximum walking time signifi-
cantly improved in both the SED and EX groups after
completion of the 12-week exercise program. At long-term
follow-up, values in the SED group returned to baseline,
while the EX group maintained increased claudication pain
time (Fig 2) of 121% above baseline and increased maxi-
mum walking time (Fig 3) of 109% above baseline (P .05).
DISCUSSION
Although studies of pharmacotherapy for claudication
often have large study populations,16-19 randomized con-
Fig 1. Values for Walking Impairment Questionnaire i
means no claudication pain; score of 0% means patient lim
exercise vs sedentary groups.
Fig 2. Values for claudication pain time in exercise and s
and at follow-up. Results represent mean SD. *P .05
progressive treadmill tests.trolled trials of supervised exercise therapy for the treat-
ment of claudication have relatively small study populations
and limited follow-up.20 Larger studies of exercise21 use
home exercise therapy or instructions, with results inferior
to those of supervised programs in short-term stud-
ies.5,22,23 Despite numerous studies demonstrating the
benefits of a supervised exercise program for treatment of
claudication,24 there is a paucity of data on the durability of
results.
Our study represents follow-up of patients who had
participated in a supervised exercise program over the pre-
ceding 80 months. Because of program changes due to
funding and administration, regular follow-up (similar to
graft surveillance) was not performed; thus our population
represents patients with a variable time to completion of the
program. The data show that continuation of an exercise
program, either supervised or at home, is necessary for
rcise and sedentary groups at follow-up. Score of 100%
by severe pain. Results represent mean SD. *P .05,
tary groups before and after supervised exercise program
program vs post-program and pre-program vs follow-upn exe
itededen
, pre-
5, pr
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ment of intermittent claudication. In addition, patients
who continue to exercise maintain a higher health-related
quality of life and greater daily functional status than do
those who discontinue training.
Although not specific for patients with PAD, the SF-36
evaluates aspects of both physical and mental health–related
quality of life, and has been extensively validated in patients
with somatic and psychiatric conditions of varying severi-
ty.9 Our results are consistent with those of previous studies
that evaluated quality of life in patients with PAD, and
found no change in the mental domain after 3 or 6 months
of exercise rehabilitation,5,7 with values close to the age-
specific population norms.9 Patients who continued to
exercise had higher scores in the physical domain, findings
supported by Bauman and Arthur,25 who found a signifi-
cant positive correlation between functional exercise capac-
ity and physical domains of the SF-36.
Because only half of the patients in our study were able
to perform a follow-up progressive treadmill test, we ad-
ministered the WIQ to better represent functional status of
the entire study population. The WIQ has been rigorously
evaluated,12 and is a satisfactory surrogate for treadmill
testing. The consistency between our total population and
patients completing follow-up treadmill testing further
strengthens our conclusions. Results from this question-
naire show that patients who continued to exercise had
significantly higher scores than sedentary patients for WIQ
distance score, speed, and stair-climbing ability.
Similarly, exercise training significantly improves both
claudication pain time and maximum walking time after 12
weeks of training, and individuals who continue exercise
training maintain improvements 20 to 80 months (mean,
4 years) after program completion. Two of the patients
who continued to exercise completed the 25-minute tread-
mill protocol without limiting claudication symptoms.
Their contribution actually underestimates the maximum
Fig 3. Values for maximum walking time in exercise and
and at follow-up. Results represent mean  SD. *P  .0walking time of the exercise group. Follow-up results for
individuals who did not continue to exercise after complet-
ing the supervised program showed that they did not
maintain improvements, and claudication pain time and
maximum walking time returned to pre-PADRx levels.
Although the ACSM defines sedentary as less than 60
minutes of weekly exercise, we were somewhat surprised at
the dramatic difference in self-reported exercise at follow-
up, which may reflect the underlying reasons for discon-
tinuing exercise. Ultimately it would be beneficial to iden-
tify characteristics of patients with PAD who are likely to
continue an exercise program. Because of the small number
of patients in this study, we were unable to define this
subset. Individually, orthopedic and arthritic complaints
were the primary reason patients discontinued exercise. In
many patients disabling arthritis developed, and their clau-
dication symptoms were no longer the limiting factor in
walking ability. Lack of motivation was also cited by several
patients as a reason for discontinuation. These patients may
benefit from more frequent follow-up, and potentially from
a structured maintenance program after the 12-week
PADRx.
General medical concerns and comorbid disease can
also limit patient functional status. In comparing the EX
and SED groups for presence of diabetes mellitus and
smoking history, the SED group had higher rates of diabe-
tes and were more likely to smoke. Patients with diabetes
are at significant risk for other comorbid conditions that
may lead to a more physically limited lifestyle. In addition
to tobacco use contributing to pulmonary, cardiac, and
PAD progression, smokers are less physically active in gen-
eral.26 Identifying physical limitations, medical comorbid
conditions, and smoking habits may help to predict which
patients will continue an exercise program after the PADRx
and to identify a patient population that will be successfully
treated with conservative management. Continuing to ex-
ercise and maintaining walking distance may primarily re-
tary groups before and after supervised exercise program
e-program vs follow-up progressive treadmill tests.seden
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and EX groups demonstrated initial improvement after
program completion, and there was no statistically signifi-
cant difference between the groups at baseline, predictors
of failure cannot be reliably determined from this study.
Few studies have compared the outcomes of exercise
therapy versus surgical or endovascular intervention, be-
cause outcomes data for assessing patency of grafts, angio-
plasty, or stents usually rely on hemodynamic measure-
ments.27 With prospective randomized trials, Creasy et al28
and Perkins et al29 compared exercise training versus per-
cutaneous transluminal angioplasty (PTA) for stable clau-
dication, using ABI and treadmill testing, with claudication
distance and mean walking distance as outcome measures.
At 15-month follow-up there was a significantly greater
improvement in the exercise training group than in those
undergoing angioplasty; however, at 60-month follow-up
outcomes were similar. Another prospective trial30 ran-
domized patients with claudication with angiographically
documented lesions amenable to PTA to either medical
treatment (aspirin, and instruction on smoking cessation
and exercise training) or PTA. At 24-month follow-up
there were no significant differences in quality-of-life mea-
sures or functional measures of ABI, patient-reported max-
imum walking distance, maximal treadmill walking dis-
tance, or distance to onset of claudication. Angiography at
follow-up did show lesser degrees of stenosis in the PTA-
treated patients; however, this did not translate into a
functional advantage.
If we define long-term success of exercise programs as
continued walking, good functional status in a community
setting, and maintained improvement in claudication
symptoms, the successful outcome rate of these study pa-
tients is 44% at a mean 48-month follow-up. If obstacles to
continued exercise, such as lack of motivation, were over-
come, perhaps more patients would benefit. Simply put, for
the treatment of intermittent claudication the success rate
of exercise therapy compares favorably with PTA and some
infrainguinal bypass studies, with very low threat to limb
viability and without the risk of surgical complications.
CONCLUSION
Although exercise therapy decreases atherosclerosis as-
sociated with PAD or change in hemodynamic measures, it
can decrease claudication symptoms, improve functional
ability, and greatly enhance quality of life in patients with
intermittent claudication. This study demonstrates that
patients who continue to exercise after completing a 12-
week vascular exercise program not only maintain greater
functional ability but also experience greater quality of life.
APPENDIX. HEALTH AND EXERCISE STATUS
EVALUATION FOR PATIENTS WITH
PERIPHERAL ARTERIAL DISEASE
General Health History
1. Since completing the exercise program have you had
any other health problems? If yes, describe.2. Since completing the program have you undergone
any major surgery or been hospitalized for any major
illness? If yes, describe.
3. Have you undergone any additional treatment for vas-
cular disease since completing the exercise program? If
yes, describe.
4. Have you continued to exercise after participating in
the vascular exercise program? If yes, are the exercises
you do similar to the ones you did in the exercise
program? Describe. If no, choose the reason that best
describes why you have not exercised.
a. General health concern.
b. Orthopedic problems.
c. Not enough time.
d. No motivation.
e. Other. Please explain.
5. What is your usual pace of walking?
6. How many flights of stairs do you walk up each day? (1
flight  10 stairs)
a. Never walk stairs.
b. 1-5.
c. 6-10.
d. Greater than 10.
Exercise Habits Since Leaving Program
7. How would you rate your current exercise habits?
a. Similar to the exercises you did during the program.
b. Less than you did at the program.
c. More than you did at the program.
8. What type of exercise do you do?
a. Walk/run.
b. Bike.
c. Swim.
d. Other. Please explain.
9. How long did you exercise after the program and then
stopped exercising regularly?
a. A couple of weeks.
b. A couple of months.
c. A couple of years.
d. I still exercise regularly.
e. I stopped immediately after the program ended. If
you have stopped, why?
10. Over the past 7 days, how often did you take a walk
outside your home or yard for any reason, eg, for fun
or exercise, walk to the store, walk the dog?
a. Never.
b. Seldom (1-2 days).
c. Sometimes (3-4 days).
d. Often (5-7 days).
11. How many times a week do you engage in regular
physical activity long enough to work up a sweat, get
your heart thumping, or get out of breath?
12. On average, how many minutes per day do you work
up a sweat, get your heart thumping, and find yourself
out of breath?
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exercises specifically to increase muscle strength and
endurance, such as lifting weights or push-ups?
a. Never.
b. Seldom (1-2 days).
c. Sometimes (3-4 days).
d. Often (5-7 days).
14. Do you feel that you can walk better today than you
could before you entered the vascular rehabilitation
exercise program?
a. Yes.
b. No.
If yes, do you think you can walk better as a result of the
vascular exercise program? Please describe.
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